Vaccines Europe pipeline review 2024
Find out more about what vaccines are in development and how they’re addressing the health challenges of tomorrow.
Our mission for the 2024 EU elections.
An EU Immunisation Strategy for an innovative, healthy and prosperous Europe
EU attractiveness for the vaccines industry
Vaccination is one of the most successful health prevention tools, protecting against several infectious diseases.
Vaccines Europe represents vaccine companies of all sizes operating in Europe
Our mission is to foster innovation and value recognition of lifecourse immunisation in Europe to protect people against evolving health challenges
Key facts and figures
Immunisation has saved 154 million lives in the last 50 years
Adult immunisation programmes return up to 19 times their initial investment
Vaccine clinical trials in the EU have dropped by 35% since 2000
There are 98 vaccine candidates in the pipelines of Vaccines Europe member companies
77% of EU member states allocate less than 0.5% of their health care budget to immunisation
In 1/3 EU countries, it takes more than 6 years for new vaccines to reach EU citizens since their regulatory approval
Highlights
-
Joint Statement of the Steering Group on Influenza Vaccination on the Council Conclusions on the improvement of cardiovascular health in the European Union
-
Patients and society set to benefit from innovation which could “alleviate significant global disease burden”
-
2024 Pipeline Review – Innovation for Unmet Need